PD-32766D/T for Kidney Cancer

This trial explores a new treatment for individuals with advanced kidney cancer that has returned or resisted other treatments. It uses a special pair of drugs, PD-32766D and PD-32766T, to identify and target cancer cells expressing a marker called CA9. The main goal is to determine the treatment's safety and behavior in the body, while also checking for any early signs of effectiveness against the cancer. Suitable candidates include those with clear cell renal cell carcinoma who have not responded to standard treatments and whose tumors show a positive reaction to the initial imaging test. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new therapy.

Research has shown that PD-32766T is being tested for safety and effectiveness in treating kidney cancer. In earlier studies, a similar compound, 64Cu-PD-32766, was well-tolerated by patients, with no serious side effects reported. This suggests the treatment might be safe for further testing.

Researchers are excited about PD-32766T for kidney cancer because it offers a new approach to treatment by using a unique imaging agent, PD-32766D, to first identify tumors that will respond to the therapy. Unlike traditional treatments such as surgery, radiation, and chemotherapy, which target cancer more generally, PD-32766T specifically targets tumors that show positive uptake of the imaging agent, potentially leading to more effective and personalized treatment. Additionally, this targeted approach may reduce side effects and improve outcomes by focusing therapy on responsive cancer cells.

Research has shown that PD-32766T targets a protein called Carbonic Anhydrase IX (CA9), often found in kidney cancer cells. This protein helps cancer cells survive in low-oxygen areas. PD-32766T is designed to attach to these CA9-expressing cells and deliver a radioactive substance to kill them. In this trial, participants in the Phase 1a Dose Escalation arm will first receive PD-32766D for imaging, and those with positive tumor uptake will then receive PD-32766T. Participants in the Phase 1b Dose Expansion arm will receive PD-32766T at recommended dose levels. Although human studies have provided limited information, the treatment's mechanism shows promise in targeting and destroying cancer cells. Early signs suggest this method could be effective against clear cell renal cell carcinoma, a type of kidney cancer. More trials are needed to confirm its effectiveness and safety.⁶⁷⁸⁹¹⁰